Compare Neurocrine Biosciences Inc (NBIX) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs PPG Industries, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $158.34 (market cap $16.46B), while PPG Industries, Inc. trades at $114.99 (market cap $25.82B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.55% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PPG | |
|---|---|---|
Market Cap | $16.46B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $131.56 |
52-Week Low | $123.10 | $94.34 |
Enterprise Value | $16.48B | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
PPG Industries trades at $115.47, down 3.55% amid bearish technical signals, though fundamentals show resilience with Q2 2026 sales up 7% year-over-year and a 4.2% dividend hike in July 2026. The stock's valuation appears reasonable with a P/E of 16.67 and P/S of 1.59, while profitability metrics like a 9.57% net margin and 19.63% ROE support operational strength. Recent leadership changes in Industrial Coatings and FTSE4Good recognition highlight ongoing corporate developments.
Wall Street maintains a bullish stance with 55% buy ratings and a $129.17 consensus target, implying 12% upside, but near-term risks include raw material cost pressures and mixed earnings performance. The technical bearish signal and proximity to support at $114 suggest cautious entry points, while the dividend aristocrat status and solid cash flow provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
